mRNA Products

Description: Firefly Luciferase (Firefly luc) expresses a luciferase protein originally extracted from fireflies. The enzyme relies on ATP to catalyze the oxidation of D-fluorescein to produce chemiluminescence at a wavelength of about 560 nm. Firefly luc is a commonly used bioluminescence reporter gene used in gene regulation and function studies. It emits biofluorescence in the presence of the substrate fluorescein. Firefly luc mRNA is synthesized and purified by one-step transcription from a linear template using T7 transcriptase and LZCapAG(3'Acm) cap analogs. The mRNA will express luciferase protein when it enters the cell. Compared with the Cap0 structure and other commercially available Cap1 structures, the Cap1 structure of LZCapAG(3'Acm) enables more efficient and durable mRNA expression. LZCapAG(3'Acm) Firefly luc mRNA stock is suitable for mRNA delivery, translation efficiency, transfection efficiency and in vivo imaging experiments.

CAT: BRP-00455

Purity: ≥90% by HPLC, 2% Agarose gel electrophoresis graph

Concentration: 1 μg/μL

Description: Enhanced Green Fluorescent Protein (eGFP) is an enhanced variant of wild-type GFP with a maximum excitation/emission wavelength of 488 nm/509 nm, respectively. eGFP, as a common reporter molecule, emits a strong green fluorescence when excited and can be detected by fluorescence microscopy or flow cytometry. eGFP mRNA was synthesized and purified from linear template one-step transcription by T7 transcriptase and LZCapAG cap analogs. The Cap1 structure of LZCapAG(3'Acm) enables more efficient and durable mRNA expression compared to the Cap0 structure and other commercially available Cap1 structures. When this mRNA enters the cell, it will express a green fluorescent protein. eGFP mRNA stock is suitable for mRNA delivery, translation efficiency, transfection efficiency and in vivo imaging experiments.

CAT: BRP-00456

Purity: ≥90% by HPLC, 2% Agarose gel electrophoresis graph

Concentration: 1 μg/μL

Description: Red fluorescent protein (RFP) is a protein isolated from the Pacific Ocean sea anemone associated Discosomasp that can emit red fluorescence under ultraviolet irradiation at a wavelength of 587 nm. LZCapAG(3'Acm) RFP mRNA was synthesized and purified from linear template one-step transcription by T7 transcriptase and LZCapAG(3'Acm). Compared with the Cap0 structure and other commercially available Cap1 structures, the Cap1 structure of LZCapAG(3'Acm) enables more efficient and durable mRNA expression. LZCapAG(3'Acm) RFP mRNA has poly A and optimized 5 'UTR and 3' UTR structure, which can improve mRNA stability and promote mRNA translation to achieve better expression effect. The immunogenicity of mRNA can be effectively reduced after m1Ψ modification. LZCapAG(3'Acm) RFP mRNA stock is suitable for mRNA delivery, translation efficiency, transfection efficiency and in vivo imaging experiments.

CAT: BRP-00457

Purity: ≥90% by HPLC, 2% Agarose gel electrophoresis graph

Concentration: 1 μg/μL

Description: The excitation/emission wavelengths of mCherry red fluorescent protein were 587 nm/610 nm, respectively. LZCapAG(3'Acm) mCherry mRNA was synthesized and purified by one-step transcription of T7 transcriptase and LZCapAG(3'Acm) cap analogs from a linear template. After co-transcription, LZCapAG(3'Acm) generates mRNA with Cap1 structure. Compared with the Cap0 structure and other commercially available Cap1 structures, the Cap1 structure of LZCapAG(3'Acm) has a more efficient and durable expression. LZCapAG(3'Acm) mCherry mRNA has poly A and optimized 5 'UTR and 3' UTR structure, which can improve mRNA stability and promote mRNA translation to achieve better expression effect. The immunogenicity of mRNA can be effectively reduced after m1Ψ modification. LZCapAG(3'Acm) mCherry mRNA will express red fluorescent protein after entering cells, which is suitable for mRNA delivery, translation efficiency, transfection efficiency and in vivo imaging experiments.

CAT: BRP-00458

Purity: ≥90% by HPLC, 2% Agarose gel electrophoresis graph

Concentration: 1 μg/μL

Description: Renilla luciferase (RLuc) is a new type of luciferase with a size of 36 kD. The enzyme can catalyze enterocelins that can penetrate cell membranes under oxygen and emit fluorescence (maximum wavelength 480 nm), the reaction is so efficient that almost all of the energy input to the reaction is converted into light. LZCapAG(3'Acm) RLuc mRNA was synthesized and purified from linear template one-step transcription by T7 transcriptase and LZCapAG(3'Acm) cap analogs. The Cap1 structure of LZCapAG(3'Acm) enables more efficient and durable mRNA expression compared to the Cap0 structure and other commercially available Cap1 structures. LZCapAG(3'Acm) RLuc mRNA has a poly A and an optimized 5 'UTR and 3' UTR structure, which can improve mRNA stability and promote mRNA translation for better expression. LZCapAG(3'Acm) RLuc mRNA stock is suitable for mRNA delivery, translation efficiency, transfection efficiency and in vivo imaging experiments.

CAT: BRP-00459

Purity: ≥90% by HPLC, 2% Agarose gel electrophoresis graph

Concentration: 1 μg/μL

Description: Gaussia Luciferase (GLuc) is the smallest (20 kD) naturally secreted luciferase known in vivo. When using Gaussia Luciferase to perform fluorescence report experiment, the cell supernatant can be directly used for detection. The luciferase catalyzes the oxidation of the substrate coelenterin and emits light (480 nm) without the involvement of ATP. LZCapAG(3'Acm) GLuc mRNA was synthesized and purified from linear template one-step transcription by T7 transcriptase and LZCapAG(3'Acm) cap analogs. Compared with the Cap0 structure and other commercially available Cap1 structures, the Cap1 structure of LZCapAG(3'Acm) enables more efficient and durable mRNA expression. LZCapAG(3'Acm) GLuc mRNA has poly A and optimized 5 'UTR and 3' UTR structure, which can improve mRNA stability and promote mRNA translation to achieve a better expression effect. LZCapAG(3'Acm) GLuc mRNA is suitable for mRNA delivery, translation efficiency and transfection efficiency experiments.

CAT: BRP-00460

Purity: ≥90% by HPLC, 2% Agarose gel electrophoresis graph

Concentration: 1 μg/μL

Description: Under the guidance of sgRNA, Cas9 protein can introduce DNA double-strand breaks (DSBS) at designated genomic locations, and cells will then activate endogenous DNA repair programs, namely non-homologous end junction (NHEJ) or homologous recombination repair mechanism (HDR), to repair the target DSB, and realize the recognition and cutting of genomic DNA targets. LZCapAG(3'Acm) Cas9 mRNA can be used with purified sgRNA to perform the cutting function with sgRNA through the expressed Cas9 protein for CRISPR/Cas genome editing. LZCapAG(3'Acm) Cas9 mRNA was synthesized and purified from linear template one-step transcription by T7 transcriptase and LZCapAG(3'Acm) cap analogs. Compared with the Cap0 structure and other commercially available Cap1 structures, the Cap1 structure of LZCapAG(3'Acm) enables more efficient and durable mRNA expression. LZCapAG(3'Acm) Cas9 mRNA has poly A and optimized 5 'UTR and 3' UTR structure, which can improve mRNA stability and promote mRNA translation to achieve a better expression effect. LZCapAG(3'Acm) Cas9 mRNA stock is suitable for mRNA delivery, translation efficiency, transfection efficiency and gene editing experiments.

CAT: BRP-00461

Purity: ≥90% by HPLC, 2% Agarose gel electrophoresis graph

Concentration: 1 μg/μL

Description: mCherry mRNA with 5-OMe-UTP (5' CAP) is a highly optimized mRNA molecule designed for efficient protein expression and reduced immunogenicity. It encodes the mCherry protein, a monomeric red fluorescent protein derived from Discosoma sp., with a maximum excitation wavelength of 587 nm and an emission wavelength of 610 nm. This mRNA features a Cap 1 structure at the 5' end, which is crucial for enhancing stability and translation efficiency. Additionally, it incorporates 5-O-Methyl-UTP (5-OMe-UTP) to further reduce immune activation and improve mRNA stability. The mRNA also includes a poly(A) tail at the 3' end, which enhances its stability and translation initiation efficiency. This modified mRNA is commonly used in various biological applications, such as studying protein expression, monitoring cellular processes, and evaluating transfection efficiency in both in vitro and in vivo studies.

CAT: BRP-02503

Concentration: 1.0 mg/mL

Description: Fluc mRNA with 5-OMe-UTP (5' CAP) is a highly optimized messenger RNA designed for efficient protein expression and reduced immunogenicity. This mRNA encodes the firefly luciferase (Fluc) protein, a widely used bioluminescent reporter gene derived from Photinus pyralis. The Fluc protein catalyzes the oxidation of luciferin to produce light with a wavelength of approximately 550-570 nm, making it an ideal tool for monitoring gene expression and cellular processes. The mRNA is synthesized using in vitro transcription and features a Cap 1 structure at the 5' end, which enhances its stability and translation efficiency. Additionally, it includes a poly(A) tail at the 3' end, further stabilizing the mRNA and promoting efficient translation. The incorporation of 5-O-Methyl-UTP (5-OMe-UTP) reduces immune activation while maintaining high mRNA stability. This product is designed for research use only and is suitable for applications such as evaluating transfection efficiency, studying gene regulation, and developing mRNA-based therapeutic strategies.

CAT: BRP-02504

Concentration: 1.0 mg/mL

Description: Cre mRNA (5' CAP) is a specialized messenger RNA designed for efficient expression of the Cre recombinase enzyme, which is widely used in genetic engineering applications such as the Cre-loxP system. This mRNA features a Cap 1 structure at the 5' end, which enhances its stability and translation efficiency. Additionally, it is polyadenylated at the 3' end to further improve stability and translation initiation. The mRNA is typically modified with nucleotides such as N1-methyl-pseudouridine (m1Ψ) or 5-Methoxyuridine to reduce immunogenicity and enhance expression efficiency. The sequence length of Cre mRNA can vary slightly depending on the supplier and specific modifications, but it generally ranges from approximately 1282 to 1425 nucleotides. Cre mRNA (5' CAP) is commonly used for applications such as conditional gene knockout, gene expression studies, and as a tool for visualizing transfection efficiency in cell-based experiments.

CAT: BRP-02505

Concentration: 1.0 mg/mL

Description: Cre mRNA with N1-Me-pUTP (5' CAP) is a specialized messenger RNA designed for efficient expression of the Cre recombinase enzyme, which is widely used in genetic engineering applications such as the Cre-loxP system. This mRNA features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, both of which enhance its stability and translation efficiency. The mRNA is also modified with N1-Methyl-pseudouridine (N1-Me-pUTP), which replaces natural uridine triphosphate (UTP) to reduce immunogenicity and further improve mRNA stability. Cre recombinase is a tyrosine recombinase that catalyzes recombination between two loxP sites, enabling precise genetic manipulation such as gene knockouts and conditional gene expression. The mRNA sequence length is typically around 1282 to 1425 nucleotides, depending on the specific product. This modified mRNA is suitable for applications in gene editing, studying gene regulation, and evaluating transfection efficiency in mammalian cells.

CAT: BRP-02506

Concentration: 1.0 mg/mL

Description: OVA mRNA with N1-Me-pUTP (5' CAP) is an optimized messenger RNA designed for efficient protein expression and reduced immunogenicity. This mRNA encodes ovalbumin (OVA), a glycoprotein commonly used as an immunogen in immune and biochemical research. OVA is a member of the chromoprotein superfamily and the main protein component in egg white, with a molecular weight of approximately 45,000 daltons. The mRNA length is approximately 1438 nucleotides. The mRNA is produced through in vitro transcription and features several modifications to enhance its stability and translation efficiency. It includes a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, both of which are crucial for reducing the immune response of host cells and increasing mRNA stability. Additionally, the mRNA is modified with N1-Methyl-pseudouridine (N1-Me-pUTP), which replaces uridine (U) to further enhance RNA stability while reducing the anti-RNA immune response. This product is suitable for applications such as establishing animal models for immune studies, evaluating transfection efficiency, and studying protein expression in mammalian cells.

CAT: BRP-02507

Concentration: 1.0 mg/mL

Description: OVA mRNA with 5-OMe-UTP (5' CAP) is a modified mRNA that incorporates 5-Methoxy-UTP (5-OMe-UTP) into the nucleotide sequence. This modification enhances the stability and translation efficiency of the mRNA while reducing its immunogenicity. The mRNA encodes Ovalbumin (OVA), a glycoprotein found in egg whites that is commonly used as an immunogen in various immune and biochemical studies, such as establishing animal models for asthma and other allergic reactions. This OVA mRNA features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, which further improves its stability and translation efficiency. The 5-OMe-UTP modification specifically helps to inhibit RNA-mediated innate immune activation, making it suitable for applications where reduced immune response is desired. This type of mRNA is ideal for cell transfection and vaccine development, providing a balance between efficient protein expression and minimized immune activation.

CAT: BRP-02508

Concentration: 1.0 mg/mL

Description: Cas9 mRNA with N1-Me-pUTP (5' CAP) is a highly optimized messenger RNA designed for efficient expression of the Cas9 protein, a key component of the CRISPR/Cas9 gene-editing system. This mRNA is produced through in vitro transcription and features a 5' Cap 1 structure and a 3' poly(A) tail, which enhance its stability and translation efficiency. The incorporation of N1-Methyl-pseudouridine (N1-Me-pUTP) replaces natural uridine (UTP), effectively reducing the immune response in mammalian cells while further stabilizing the mRNA. The CRISPR/Cas9 system is widely used for precise genome editing by introducing double-strand breaks at specific DNA locations guided by single-guide RNA (sgRNA), enabling targeted gene modifications. This optimized Cas9 mRNA is suitable for applications such as gene editing, functional genomics studies, and the development of gene therapies. It should be used in conjunction with purified guide RNA (sgRNA) to achieve efficient genome editing.

CAT: BRP-02509

Concentration: 1.0 mg/mL

Description: mCherry mRNA with N1-Me-pUTP (5' CAP) is a highly optimized messenger RNA designed for efficient expression of the mCherry protein, a widely used red fluorescent protein with excitation/emission wavelengths of 587 nm/610 nm. This mRNA features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, both of which enhance its stability and translation efficiency. Additionally, it incorporates N1-Methyl-pseudouridine (N1-Me-pUTP) to replace natural uridine, effectively reducing the immune response in mammalian cells while further stabilizing the mRNA. This modification also increases ribosome density and enhances translation efficiency through both eIF2α-dependent and independent mechanisms. The mCherry mRNA can be used as a standard to test the transfection efficiency of different reagents and serves as a control for studying the transfection and expression of fluorescent proteins in mammalian cells. It is suitable for applications such as monitoring gene expression, studying cellular processes, and evaluating transfection efficiency in both in vitro and in vivo studies.

CAT: BRP-02510

Concentration: 1.0 mg/mL

Description: OVA mRNA (5' CAP) is a synthetic messenger RNA designed for efficient expression of the ovalbumin (OVA) protein, which is commonly used as an immunogenic protein in various research applications. This mRNA features a 5' cap structure, which enhances its stability and translation efficiency. The 5' cap is crucial for protecting the mRNA from degradation and facilitating efficient translation initiation. The incorporation of a 5' cap structure is a standard modification in synthetic mRNA design to improve its overall stability and functionality. This modification helps in reducing the innate immune response, which is a common challenge in mRNA-based therapies and vaccines. Additionally, the use of such modifications can enhance the half-life of the mRNA, allowing for more prolonged and efficient protein expression. OVA mRNA (5' CAP) is suitable for applications such as studying immune responses, evaluating transfection efficiency, and developing mRNA-based vaccines and therapeutics. The specific modifications and optimizations in the mRNA design ensure that it can be effectively used in both in vitro and in vivo studies.

CAT: BRP-02511

Concentration: 1.0 mg/mL

Description: Cas9 mRNA (5' CAP) is a specialized messenger RNA designed for efficient expression of the CRISPR-associated protein 9 (Cas9), a key component of the CRISPR/Cas9 gene-editing system. This mRNA features a 5' cap structure, which enhances its stability and translation efficiency. The CRISPR/Cas9 system is a powerful tool for genome editing, allowing precise modifications to the DNA sequence by introducing double-strand breaks at specific locations, guided by a single-guide RNA (sgRNA). The Cas9 protein, encoded by the mRNA, is responsible for cleaving the target DNA, which can then be repaired through cellular mechanisms such as non-homologous end joining (NHEJ) or homology-directed repair (HDR). Cas9 mRNA (5' CAP) is widely used in various applications, including basic research, gene therapy, and the development of treatments for genetic diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders. The use of a 5' cap structure helps to protect the mRNA from degradation and enhances its overall functionality, making it a valuable tool for both in vitro and in vivo studies.

CAT: BRP-02512

Concentration: 1.0 mg/mL

Description: mCherry mRNA (5' CAP) is a high-quality messenger RNA designed for efficient expression of the mCherry protein, a monomeric red fluorescent protein derived from Discosoma sp. This mRNA features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, which enhance its stability and translation efficiency. The Cap 1 structure is particularly important as it mimics the natural cap found in eukaryotic mRNA, reducing immune responses and improving protein expression. The poly(A) tail further stabilizes the mRNA and promotes efficient translation. mCherry protein has a maximum excitation wavelength at 587 nm and an emission wavelength at 610 nm, making it an ideal tool for fluorescence microscopy and live-cell imaging. This mRNA can be used as a standard to test the transfection efficiency of different reagents and serves as a control for studying the transfection and expression of fluorescent proteins in mammalian cells. It is suitable for applications such as molecular tagging, cell component localization, and monitoring gene expression.

CAT: BRP-02513

Appearance: Colorless and transparent liquid

Concentration: 1.0 mg/mL

Description: Fluc-eGFP mRNA with N1-Me-pUTP (5' CAP) is a highly optimized dual-reporter mRNA designed for efficient expression of both firefly luciferase (Fluc) and enhanced green fluorescent protein (eGFP) in mammalian cells. This mRNA is produced through in vitro transcription and features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, both of which enhance its stability and translation efficiency. The mRNA incorporates N1-Methyl-pseudouridine (N1-Me-pUTP) to replace natural uridine triphosphate (UTP), which significantly reduces the immune response in mammalian cells while improving mRNA stability and translation efficiency. The Fluc-eGFP mRNA encodes a fusion protein with a P2A self-cleaving peptide sequence that allows for the expression of two independent proteins (eGFP and luciferase) after translation. This dual-reporter system enables both fluorescence and bioluminescence detection: eGFP fluorescence can be monitored using a fluorescence microscope (excitation/emission wavelengths: 488 nm/509 nm), while luciferase activity can be measured through bioluminescent assays. This dual-reporting capability makes it an ideal tool for evaluating transfection and delivery efficiency in both cell-based and animal studies. The mRNA is optimized with high proportion (>95%) of Cap1 structures and optimized codons, UTRs, and poly(A) sequences for enhanced expression in mammalian cells. This product is suitable for applications such as gene regulation studies, transfection efficiency assessments, and in vivo imaging studies.

CAT: BRP-02514

Concentration: 1.0 mg/mL

Description: Fluc-eGFP mRNA (5' CAP) is a versatile dual-reporter mRNA designed for efficient expression of both firefly luciferase (Fluc) and enhanced green fluorescent protein (eGFP). This mRNA features a Cap 1 structure at the 5' end and a poly(A) tail at the 3' end, which enhance its stability and translation efficiency. The mRNA is optimized with N1-Methyl-pseudouridine (N1-Me-pUTP) to replace natural uridine, reducing immunogenicity and improving expression efficiency. The Fluc-eGFP mRNA encodes a fusion protein with a P2A self-cleaving peptide sequence that allows for the expression of two independent proteins (eGFP and luciferase) after translation. This dual-reporter system enables both fluorescence and bioluminescence detection: eGFP fluorescence can be monitored using a fluorescence microscope (excitation/emission wavelengths: 488 nm/509 nm), while luciferase activity can be measured through bioluminescent assays. This dual-reporting capability makes it an ideal tool for evaluating transfection and delivery efficiency in both cell-based and animal studies. The mRNA is produced using a co-transcriptional capping process, resulting in a high proportion (>95%) of Cap1 structures and optimized codons, UTRs, and poly(A) sequences for enhanced expression in mammalian cells. The product is highly pure, with mRNA integrity exceeding 90% and a capping rate of over 95%. This optimized mRNA can be directly used for formulation development and delivery efficiency assessment, making it a valuable tool for mRNA vaccine and drug research.

CAT: BRP-02515

Concentration: 1.0 mg/mL